By: IPP Bureau
Last updated : September 13, 2025 7:31 am
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Takeda announced that Rhonda Pacheco, most recently group vice president of US Cardiometabolic Health at Eli Lilly, will join Takeda, effective September 29, as president of Takeda’s U.S. Business Unit and will be a member of the Takeda Executive Team.
Pacheco will succeed Julie Kim, who was appointed by the Takeda Board of Directors to succeed Christophe Weber as president & Chief Executive Officer (CEO) of Takeda in June 2026. With Pacheco’s appointment, Kim will focus on preparing for the CEO transition, which includes serving as interim head of the Global Portfolio Division.
Pacheco comes to Takeda from Eli Lilly where she oversaw complex portfolios in a range of leadership roles, including successful product launches, most recently its GLP1 portfolio, and delivered strong commercial performance.
Pacheco, a Massachusetts native, holds an MBA from Duke University’s Fuqua School of Business and a doctorate of pharmacy from the University of Rhode Island.